Fenghuang Zhan
Concepts (553)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 135 | 2025 | 2998 | 9.920 |
Why?
| Gene Expression Regulation, Neoplastic | 53 | 2025 | 833 | 3.280 |
Why?
| Drug Resistance, Neoplasm | 25 | 2020 | 316 | 3.140 |
Why?
| Gene Expression Profiling | 43 | 2023 | 1025 | 2.760 |
Why?
| Cell Proliferation | 25 | 2022 | 985 | 2.190 |
Why?
| Plasma Cells | 23 | 2025 | 221 | 2.180 |
Why?
| Antineoplastic Agents | 29 | 2020 | 1172 | 2.110 |
Why?
| Cell Line, Tumor | 46 | 2025 | 1398 | 1.950 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 8 | 2024 | 112 | 1.890 |
Why?
| Neoplastic Stem Cells | 7 | 2020 | 98 | 1.650 |
Why?
| Pyrazines | 19 | 2023 | 188 | 1.560 |
Why?
| Paraproteinemias | 9 | 2024 | 72 | 1.430 |
Why?
| Mice | 46 | 2025 | 5687 | 1.420 |
Why?
| Lymphoma, B-Cell | 5 | 2021 | 49 | 1.410 |
Why?
| Apoptosis | 18 | 2025 | 1097 | 1.380 |
Why?
| Disease Progression | 18 | 2024 | 829 | 1.370 |
Why?
| Humans | 155 | 2025 | 50503 | 1.350 |
Why?
| Boronic Acids | 17 | 2014 | 183 | 1.350 |
Why?
| Bone Resorption | 6 | 2024 | 302 | 1.350 |
Why?
| Tumor Microenvironment | 6 | 2024 | 222 | 1.240 |
Why?
| Animals | 57 | 2025 | 13124 | 1.230 |
Why?
| Neoplasm Proteins | 7 | 2021 | 320 | 1.180 |
Why?
| Prognosis | 36 | 2024 | 1978 | 1.120 |
Why?
| Osteolysis | 4 | 2022 | 74 | 1.100 |
Why?
| B-Lymphocytes | 8 | 2021 | 171 | 1.070 |
Why?
| Cell Cycle Proteins | 4 | 2023 | 161 | 1.020 |
Why?
| T-Lymphocytes | 8 | 2024 | 325 | 0.990 |
Why?
| Hematopoietic Stem Cell Transplantation | 6 | 2024 | 578 | 0.980 |
Why?
| Ubiquitination | 3 | 2021 | 42 | 0.930 |
Why?
| Proteasome Inhibitors | 7 | 2020 | 104 | 0.910 |
Why?
| Signal Transduction | 21 | 2023 | 1624 | 0.870 |
Why?
| MicroRNAs | 7 | 2022 | 344 | 0.820 |
Why?
| Proteasome Endopeptidase Complex | 4 | 2018 | 116 | 0.820 |
Why?
| Antigens, CD | 8 | 2024 | 222 | 0.760 |
Why?
| Neoplasms | 3 | 2024 | 1251 | 0.740 |
Why?
| Carrier Proteins | 3 | 2017 | 298 | 0.670 |
Why?
| CDC2-CDC28 Kinases | 3 | 2015 | 11 | 0.660 |
Why?
| Cation Transport Proteins | 2 | 2019 | 27 | 0.640 |
Why?
| Up-Regulation | 6 | 2020 | 446 | 0.620 |
Why?
| Ubiquitins | 2 | 2016 | 39 | 0.620 |
Why?
| Cyclin-Dependent Kinases | 2 | 2010 | 26 | 0.620 |
Why?
| Mice, Inbred NOD | 5 | 2020 | 91 | 0.610 |
Why?
| Glycolysis | 3 | 2022 | 69 | 0.610 |
Why?
| Oligonucleotide Array Sequence Analysis | 19 | 2014 | 405 | 0.610 |
Why?
| Waldenstrom Macroglobulinemia | 1 | 2018 | 40 | 0.600 |
Why?
| Chromosome Aberrations | 6 | 2023 | 280 | 0.590 |
Why?
| Proto-Oncogene Proteins c-akt | 5 | 2023 | 156 | 0.590 |
Why?
| Cell Differentiation | 9 | 2023 | 640 | 0.590 |
Why?
| Iron | 2 | 2017 | 121 | 0.580 |
Why?
| STAT3 Transcription Factor | 4 | 2016 | 77 | 0.570 |
Why?
| Pyrimidines | 3 | 2015 | 191 | 0.570 |
Why?
| Killer Cells, Natural | 5 | 2024 | 106 | 0.560 |
Why?
| Cell Survival | 10 | 2020 | 589 | 0.560 |
Why?
| Ascorbic Acid | 1 | 2017 | 21 | 0.550 |
Why?
| Pyruvate Kinase | 1 | 2017 | 7 | 0.550 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1000 | 0.540 |
Why?
| RNA Splicing | 1 | 2017 | 38 | 0.540 |
Why?
| Protein-Tyrosine Kinases | 2 | 2015 | 88 | 0.510 |
Why?
| Down-Regulation | 9 | 2019 | 340 | 0.500 |
Why?
| Cyclopentanes | 1 | 2015 | 10 | 0.500 |
Why?
| Transplantation, Autologous | 5 | 2024 | 481 | 0.490 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 67 | 0.490 |
Why?
| Thalidomide | 10 | 2023 | 378 | 0.490 |
Why?
| Aldehyde Dehydrogenase | 1 | 2014 | 25 | 0.480 |
Why?
| Osteoclasts | 7 | 2023 | 427 | 0.470 |
Why?
| Dexamethasone | 7 | 2024 | 432 | 0.460 |
Why?
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2020 | 17 | 0.460 |
Why?
| Female | 44 | 2024 | 27081 | 0.440 |
Why?
| Models, Biological | 5 | 2018 | 716 | 0.440 |
Why?
| Hematologic Neoplasms | 1 | 2015 | 99 | 0.430 |
Why?
| Receptors, Retinoic Acid | 2 | 2013 | 22 | 0.430 |
Why?
| Cystatin M | 2 | 2024 | 19 | 0.430 |
Why?
| Male | 34 | 2024 | 25907 | 0.430 |
Why?
| RNA, Messenger | 13 | 2021 | 1089 | 0.420 |
Why?
| Flow Cytometry | 8 | 2018 | 474 | 0.410 |
Why?
| B-Cell Maturation Antigen | 2 | 2024 | 99 | 0.410 |
Why?
| Antigens, Neoplasm | 6 | 2014 | 148 | 0.410 |
Why?
| Glucuronidase | 4 | 2018 | 48 | 0.400 |
Why?
| Predictive Value of Tests | 5 | 2016 | 930 | 0.380 |
Why?
| Mice, Transgenic | 6 | 2021 | 540 | 0.370 |
Why?
| Antibodies, Bispecific | 2 | 2023 | 88 | 0.370 |
Why?
| Syndecan-1 | 6 | 2017 | 75 | 0.360 |
Why?
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 5 | 0.360 |
Why?
| Arsenicals | 1 | 2010 | 14 | 0.360 |
Why?
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 20 | 0.360 |
Why?
| Oxides | 1 | 2010 | 18 | 0.360 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 12 | 2015 | 572 | 0.350 |
Why?
| Janus Kinase 1 | 1 | 2010 | 16 | 0.350 |
Why?
| Proto-Oncogene Proteins c-jun | 2 | 2009 | 77 | 0.350 |
Why?
| MAP Kinase Kinase 1 | 1 | 2010 | 23 | 0.340 |
Why?
| Immunotherapy, Adoptive | 2 | 2024 | 163 | 0.340 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 80 | 0.340 |
Why?
| DNA-Binding Proteins | 4 | 2021 | 418 | 0.340 |
Why?
| Early Growth Response Protein 1 | 1 | 2009 | 34 | 0.330 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 2 | 2024 | 90 | 0.320 |
Why?
| Transcription Factors | 6 | 2022 | 565 | 0.320 |
Why?
| Tretinoin | 1 | 2009 | 50 | 0.320 |
Why?
| Oligopeptides | 3 | 2015 | 95 | 0.310 |
Why?
| Xenograft Model Antitumor Assays | 7 | 2019 | 212 | 0.310 |
Why?
| NF-kappa B | 3 | 2018 | 315 | 0.300 |
Why?
| Osteogenesis | 5 | 2023 | 356 | 0.300 |
Why?
| Genes, Neoplasm | 1 | 2008 | 27 | 0.300 |
Why?
| Tumor Cells, Cultured | 6 | 2020 | 457 | 0.300 |
Why?
| Antibodies | 3 | 2024 | 153 | 0.290 |
Why?
| Microarray Analysis | 3 | 2018 | 70 | 0.290 |
Why?
| Aged | 24 | 2024 | 9741 | 0.290 |
Why?
| Chromosomes, Human, Pair 1 | 4 | 2023 | 92 | 0.280 |
Why?
| Immunologic Factors | 5 | 2015 | 111 | 0.280 |
Why?
| Interleukin-6 | 3 | 2019 | 261 | 0.280 |
Why?
| S-Phase Kinase-Associated Proteins | 1 | 2007 | 2 | 0.280 |
Why?
| Neoplasms, Plasma Cell | 2 | 2023 | 36 | 0.280 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2008 | 213 | 0.280 |
Why?
| Small Molecule Libraries | 2 | 2019 | 67 | 0.270 |
Why?
| Pyrazoles | 2 | 2020 | 111 | 0.270 |
Why?
| Mice, SCID | 9 | 2018 | 178 | 0.260 |
Why?
| Protein Kinase Inhibitors | 3 | 2024 | 204 | 0.250 |
Why?
| CD8-Positive T-Lymphocytes | 3 | 2024 | 125 | 0.250 |
Why?
| Endopeptidase Clp | 1 | 2025 | 2 | 0.250 |
Why?
| Risk Factors | 11 | 2018 | 3724 | 0.250 |
Why?
| Genomics | 2 | 2023 | 279 | 0.240 |
Why?
| Survival Rate | 8 | 2020 | 909 | 0.240 |
Why?
| Enzyme Inhibitors | 4 | 2019 | 377 | 0.240 |
Why?
| Middle Aged | 23 | 2024 | 12611 | 0.240 |
Why?
| Bone Diseases | 4 | 2016 | 96 | 0.240 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2021 | 46 | 0.230 |
Why?
| Bone Marrow | 7 | 2024 | 363 | 0.230 |
Why?
| Single-Cell Analysis | 1 | 2025 | 63 | 0.230 |
Why?
| Receptors, LDL | 1 | 2024 | 67 | 0.220 |
Why?
| Hydroxybenzoates | 1 | 2024 | 18 | 0.220 |
Why?
| Propionates | 1 | 2024 | 22 | 0.220 |
Why?
| Ferritins | 1 | 2024 | 30 | 0.220 |
Why?
| TNF Receptor-Associated Factor 3 | 2 | 2022 | 13 | 0.220 |
Why?
| Myeloid Progenitor Cells | 1 | 2023 | 17 | 0.220 |
Why?
| X-Ray Microtomography | 1 | 2024 | 79 | 0.220 |
Why?
| Cholesterol | 1 | 2024 | 150 | 0.220 |
Why?
| Melphalan | 3 | 2023 | 178 | 0.220 |
Why?
| Histocompatibility Antigens Class I | 2 | 2015 | 46 | 0.220 |
Why?
| Antigens, CD19 | 3 | 2018 | 29 | 0.220 |
Why?
| Neoplasms, Second Primary | 1 | 2024 | 74 | 0.220 |
Why?
| Bone Marrow Cells | 4 | 2015 | 196 | 0.220 |
Why?
| Cell Transformation, Neoplastic | 1 | 2024 | 181 | 0.210 |
Why?
| Membrane Glycoproteins | 6 | 2009 | 245 | 0.210 |
Why?
| Proto-Oncogene Proteins c-myc | 3 | 2025 | 50 | 0.210 |
Why?
| Genes, myc | 3 | 2019 | 32 | 0.210 |
Why?
| Intercellular Signaling Peptides and Proteins | 4 | 2007 | 102 | 0.210 |
Why?
| Lymphoma | 1 | 2024 | 67 | 0.210 |
Why?
| Bone Diseases, Metabolic | 1 | 2024 | 74 | 0.210 |
Why?
| Phenols | 1 | 2024 | 82 | 0.210 |
Why?
| Cluster Analysis | 5 | 2009 | 219 | 0.210 |
Why?
| Homeostasis | 1 | 2024 | 204 | 0.210 |
Why?
| Gene Knockdown Techniques | 3 | 2018 | 105 | 0.210 |
Why?
| Bone and Bones | 2 | 2021 | 478 | 0.210 |
Why?
| NM23 Nucleoside Diphosphate Kinases | 1 | 2022 | 4 | 0.210 |
Why?
| Recurrence | 7 | 2018 | 659 | 0.200 |
Why?
| Protein Binding | 2 | 2018 | 654 | 0.200 |
Why?
| Neutropenia | 1 | 2023 | 116 | 0.200 |
Why?
| Periodontitis | 1 | 2022 | 13 | 0.200 |
Why?
| Randomized Controlled Trials as Topic | 6 | 2016 | 573 | 0.200 |
Why?
| In Situ Hybridization, Fluorescence | 5 | 2023 | 231 | 0.200 |
Why?
| Antibodies, Monoclonal | 3 | 2013 | 462 | 0.200 |
Why?
| Reactive Oxygen Species | 4 | 2017 | 409 | 0.200 |
Why?
| Case-Control Studies | 8 | 2020 | 1156 | 0.200 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 154 | 0.190 |
Why?
| Protein Stability | 2 | 2020 | 43 | 0.190 |
Why?
| Kaplan-Meier Estimate | 5 | 2016 | 464 | 0.190 |
Why?
| Osteoporosis | 1 | 2023 | 156 | 0.190 |
Why?
| Mitochondria | 1 | 2025 | 399 | 0.190 |
Why?
| Arthritis, Rheumatoid | 1 | 2022 | 106 | 0.190 |
Why?
| Adult | 20 | 2024 | 13577 | 0.190 |
Why?
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2021 | 1 | 0.190 |
Why?
| Nuclear Factor 90 Proteins | 1 | 2021 | 1 | 0.190 |
Why?
| RANK Ligand | 1 | 2022 | 187 | 0.180 |
Why?
| Ubiquitin-Protein Ligases | 2 | 2020 | 95 | 0.180 |
Why?
| Venous Thromboembolism | 3 | 2011 | 74 | 0.180 |
Why?
| Oxidative Stress | 4 | 2016 | 772 | 0.180 |
Why?
| Phenylpropionates | 1 | 2021 | 13 | 0.180 |
Why?
| Hippurates | 1 | 2021 | 10 | 0.180 |
Why?
| Gene Expression | 4 | 2017 | 610 | 0.180 |
Why?
| Cell Cycle | 4 | 2010 | 226 | 0.180 |
Why?
| Membrane Proteins | 3 | 2017 | 332 | 0.180 |
Why?
| Proteolysis | 3 | 2017 | 96 | 0.180 |
Why?
| Bone Neoplasms | 2 | 2015 | 179 | 0.180 |
Why?
| Colonic Neoplasms | 1 | 2022 | 158 | 0.180 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 198 | 0.180 |
Why?
| Protease Inhibitors | 3 | 2011 | 58 | 0.180 |
Why?
| Cell Movement | 2 | 2015 | 247 | 0.180 |
Why?
| Treatment Outcome | 12 | 2020 | 5283 | 0.180 |
Why?
| Colorectal Neoplasms | 2 | 2022 | 260 | 0.180 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2021 | 49 | 0.180 |
Why?
| Antigens, CD20 | 2 | 2014 | 6 | 0.180 |
Why?
| Neoplasm Metastasis | 4 | 2015 | 232 | 0.170 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2015 | 46 | 0.170 |
Why?
| Retrospective Studies | 7 | 2024 | 6263 | 0.170 |
Why?
| Time Factors | 8 | 2021 | 2935 | 0.170 |
Why?
| Disease-Free Survival | 7 | 2016 | 444 | 0.170 |
Why?
| Evolution, Molecular | 1 | 2021 | 95 | 0.170 |
Why?
| Chromosomal Instability | 3 | 2021 | 16 | 0.170 |
Why?
| Cytotoxicity, Immunologic | 4 | 2015 | 55 | 0.170 |
Why?
| Tumor Suppressor Proteins | 2 | 2019 | 128 | 0.170 |
Why?
| Clinical Trials as Topic | 1 | 2022 | 486 | 0.170 |
Why?
| Neoplasm Recurrence, Local | 1 | 2024 | 629 | 0.170 |
Why?
| DNA, Single-Stranded | 1 | 2020 | 89 | 0.160 |
Why?
| NF-E2-Related Factor 2 | 1 | 2019 | 40 | 0.160 |
Why?
| Oncogene Proteins | 1 | 2019 | 16 | 0.160 |
Why?
| Mitosis | 3 | 2015 | 88 | 0.160 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2019 | 23 | 0.160 |
Why?
| Transplantation, Heterologous | 2 | 2017 | 75 | 0.160 |
Why?
| rab GTP-Binding Proteins | 1 | 2019 | 35 | 0.160 |
Why?
| Receptors, Interleukin-6 | 1 | 2018 | 22 | 0.160 |
Why?
| Healthcare Disparities | 1 | 2022 | 281 | 0.160 |
Why?
| Pyridines | 1 | 2019 | 131 | 0.150 |
Why?
| Drug Tolerance | 1 | 2018 | 60 | 0.150 |
Why?
| Neovascularization, Pathologic | 3 | 2009 | 155 | 0.150 |
Why?
| Blotting, Western | 3 | 2015 | 578 | 0.150 |
Why?
| Lung Neoplasms | 1 | 2024 | 601 | 0.150 |
Why?
| Drug Therapy, Combination | 2 | 2017 | 384 | 0.140 |
Why?
| beta Catenin | 2 | 2015 | 97 | 0.140 |
Why?
| Mice, Knockout | 4 | 2023 | 844 | 0.140 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2017 | 4 | 0.140 |
Why?
| Hydroxamic Acids | 2 | 2014 | 37 | 0.140 |
Why?
| Aerobiosis | 1 | 2017 | 14 | 0.140 |
Why?
| Microfilament Proteins | 1 | 2017 | 42 | 0.140 |
Why?
| Onium Compounds | 1 | 2016 | 13 | 0.140 |
Why?
| Thyroid Hormones | 1 | 2017 | 20 | 0.140 |
Why?
| Calcium-Binding Proteins | 1 | 2017 | 55 | 0.140 |
Why?
| Organophosphorus Compounds | 1 | 2016 | 15 | 0.140 |
Why?
| Deoxyglucose | 1 | 2016 | 36 | 0.140 |
Why?
| Histone Deacetylase Inhibitors | 2 | 2014 | 56 | 0.140 |
Why?
| Survival Analysis | 6 | 2020 | 661 | 0.130 |
Why?
| Inhibitor of Apoptosis Proteins | 3 | 2015 | 21 | 0.130 |
Why?
| Gene Deletion | 2 | 2008 | 261 | 0.130 |
Why?
| Pancreatic Neoplasms | 1 | 2019 | 206 | 0.130 |
Why?
| Syndecans | 3 | 2006 | 37 | 0.130 |
Why?
| RNA Interference | 2 | 2015 | 178 | 0.130 |
Why?
| Aged, 80 and over | 7 | 2021 | 3226 | 0.130 |
Why?
| Cell Death | 1 | 2016 | 175 | 0.130 |
Why?
| Ribosomal Proteins | 1 | 2016 | 24 | 0.130 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 45 | 0.130 |
Why?
| Proto-Oncogene Proteins | 2 | 2009 | 145 | 0.130 |
Why?
| Proteoglycans | 3 | 2006 | 83 | 0.130 |
Why?
| Macrophages | 2 | 2022 | 364 | 0.130 |
Why?
| Oncolytic Virotherapy | 1 | 2015 | 18 | 0.130 |
Why?
| Gene Dosage | 2 | 2013 | 74 | 0.120 |
Why?
| Cell Adhesion Molecules | 1 | 2015 | 86 | 0.120 |
Why?
| Polysaccharides | 1 | 2015 | 51 | 0.120 |
Why?
| Core Binding Factor Alpha 1 Subunit | 1 | 2015 | 44 | 0.120 |
Why?
| Receptors, Transferrin | 1 | 2015 | 16 | 0.120 |
Why?
| Side-Population Cells | 1 | 2015 | 3 | 0.120 |
Why?
| Lentivirus | 1 | 2015 | 17 | 0.120 |
Why?
| Serine Endopeptidases | 2 | 2006 | 51 | 0.120 |
Why?
| Retinal Dehydrogenase | 1 | 2014 | 10 | 0.120 |
Why?
| Receptors, Cell Surface | 1 | 2015 | 116 | 0.120 |
Why?
| Adenine | 1 | 2015 | 31 | 0.120 |
Why?
| Caspase 3 | 2 | 2022 | 93 | 0.120 |
Why?
| Serum | 1 | 2014 | 32 | 0.120 |
Why?
| Cell Lineage | 1 | 2014 | 83 | 0.120 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 34 | 0.120 |
Why?
| Translocation, Genetic | 4 | 2021 | 240 | 0.110 |
Why?
| Superoxide Dismutase | 1 | 2014 | 116 | 0.110 |
Why?
| Tumor Burden | 3 | 2020 | 130 | 0.110 |
Why?
| Piperidines | 1 | 2015 | 99 | 0.110 |
Why?
| Cyclins | 3 | 2015 | 38 | 0.110 |
Why?
| HLA Antigens | 1 | 2014 | 52 | 0.110 |
Why?
| Alkaline Phosphatase | 2 | 2011 | 93 | 0.110 |
Why?
| Glycoproteins | 1 | 2014 | 116 | 0.110 |
Why?
| Repressor Proteins | 4 | 2015 | 148 | 0.110 |
Why?
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2013 | 12 | 0.110 |
Why?
| Leukemia, Plasma Cell | 1 | 2013 | 32 | 0.110 |
Why?
| Lactate Dehydrogenases | 1 | 2013 | 1 | 0.110 |
Why?
| Phenotype | 4 | 2009 | 739 | 0.110 |
Why?
| Genome, Human | 2 | 2021 | 109 | 0.110 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2013 | 62 | 0.100 |
Why?
| Follow-Up Studies | 5 | 2024 | 2242 | 0.100 |
Why?
| Dose-Response Relationship, Drug | 4 | 2020 | 1372 | 0.100 |
Why?
| Scavenger Receptors, Class A | 1 | 2013 | 39 | 0.100 |
Why?
| Leukemia | 1 | 2013 | 65 | 0.100 |
Why?
| Disease Models, Animal | 4 | 2020 | 1436 | 0.100 |
Why?
| bcl-X Protein | 1 | 2013 | 53 | 0.100 |
Why?
| Heat-Shock Proteins | 1 | 2013 | 100 | 0.100 |
Why?
| RNA, Small Interfering | 2 | 2010 | 208 | 0.100 |
Why?
| RNA, Neoplasm | 3 | 2007 | 43 | 0.100 |
Why?
| Forkhead Transcription Factors | 2 | 2023 | 110 | 0.100 |
Why?
| Clinical Trials, Phase III as Topic | 2 | 2012 | 45 | 0.100 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2011 | 22 | 0.100 |
Why?
| Drug Screening Assays, Antitumor | 3 | 2020 | 131 | 0.100 |
Why?
| Activated Protein C Resistance | 1 | 2011 | 10 | 0.090 |
Why?
| Factor V | 1 | 2011 | 11 | 0.090 |
Why?
| Protein Isoforms | 2 | 2009 | 116 | 0.090 |
Why?
| Acetylcysteine | 1 | 2011 | 101 | 0.090 |
Why?
| Glucocorticoids | 1 | 2013 | 230 | 0.090 |
Why?
| Interferon Regulatory Factor-1 | 1 | 2010 | 14 | 0.090 |
Why?
| Cell Growth Processes | 1 | 2010 | 22 | 0.090 |
Why?
| HLA-A Antigens | 2 | 2007 | 10 | 0.090 |
Why?
| Cells, Cultured | 6 | 2015 | 1571 | 0.090 |
Why?
| Gene Silencing | 2 | 2007 | 115 | 0.080 |
Why?
| Alleles | 2 | 2021 | 256 | 0.080 |
Why?
| Epigenesis, Genetic | 2 | 2023 | 372 | 0.080 |
Why?
| Thrombosis | 1 | 2012 | 250 | 0.080 |
Why?
| Immunophenotyping | 5 | 2010 | 105 | 0.080 |
Why?
| K562 Cells | 3 | 2016 | 40 | 0.080 |
Why?
| Microtubule-Associated Proteins | 1 | 2009 | 66 | 0.080 |
Why?
| Recombinant Proteins | 1 | 2010 | 476 | 0.080 |
Why?
| Bone Remodeling | 1 | 2010 | 149 | 0.080 |
Why?
| Chromosome Mapping | 2 | 2006 | 153 | 0.080 |
Why?
| Thromboembolism | 1 | 2009 | 55 | 0.080 |
Why?
| Neoplasm Staging | 3 | 2024 | 746 | 0.080 |
Why?
| Mutation | 3 | 2021 | 1280 | 0.080 |
Why?
| Lymphocyte Subsets | 1 | 2008 | 14 | 0.080 |
Why?
| Receptors, Immunologic | 1 | 2008 | 35 | 0.070 |
Why?
| ras Proteins | 2 | 2020 | 64 | 0.070 |
Why?
| Angiogenesis Inhibitors | 1 | 2009 | 183 | 0.070 |
Why?
| Neoplasm Transplantation | 2 | 2020 | 86 | 0.070 |
Why?
| G2 Phase Cell Cycle Checkpoints | 2 | 2020 | 9 | 0.070 |
Why?
| Patient Selection | 1 | 2009 | 259 | 0.070 |
Why?
| Adoptive Transfer | 1 | 2007 | 30 | 0.070 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2007 | 23 | 0.070 |
Why?
| Genes, abl | 1 | 2007 | 2 | 0.070 |
Why?
| Gene Expression Regulation | 2 | 2022 | 955 | 0.070 |
Why?
| Breast Neoplasms | 2 | 2007 | 1201 | 0.070 |
Why?
| HEK293 Cells | 2 | 2019 | 213 | 0.070 |
Why?
| Cancer Vaccines | 1 | 2007 | 80 | 0.070 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2007 | 71 | 0.070 |
Why?
| Drug Evaluation, Preclinical | 2 | 2021 | 145 | 0.070 |
Why?
| Caspases | 1 | 2007 | 103 | 0.070 |
Why?
| Cyclin D | 1 | 2006 | 18 | 0.070 |
Why?
| Chromosome Banding | 1 | 2006 | 18 | 0.070 |
Why?
| Proportional Hazards Models | 2 | 2024 | 415 | 0.070 |
Why?
| Models, Genetic | 1 | 2006 | 172 | 0.070 |
Why?
| Palatine Tonsil | 2 | 2003 | 11 | 0.070 |
Why?
| Peptides | 1 | 2007 | 221 | 0.060 |
Why?
| DNA Damage | 1 | 2008 | 301 | 0.060 |
Why?
| Maf Transcription Factors, Large | 1 | 2005 | 1 | 0.060 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 179 | 0.060 |
Why?
| Data Interpretation, Statistical | 1 | 2006 | 162 | 0.060 |
Why?
| Doxorubicin | 2 | 2018 | 236 | 0.060 |
Why?
| Protein Kinases | 1 | 2005 | 71 | 0.060 |
Why?
| Cyclin D1 | 1 | 2005 | 52 | 0.060 |
Why?
| Antibody Formation | 1 | 2005 | 50 | 0.060 |
Why?
| Protein Biosynthesis | 2 | 2003 | 232 | 0.060 |
Why?
| Mice, Inbred C57BL | 2 | 2021 | 1808 | 0.060 |
Why?
| Cystadenocarcinoma, Serous | 1 | 2004 | 71 | 0.060 |
Why?
| Papillomaviridae | 1 | 2005 | 103 | 0.060 |
Why?
| Base Sequence | 3 | 2015 | 639 | 0.060 |
Why?
| Carcinoma, Papillary | 1 | 2004 | 47 | 0.060 |
Why?
| Transfection | 2 | 2020 | 356 | 0.060 |
Why?
| Transcription, Genetic | 1 | 2005 | 361 | 0.060 |
Why?
| Mice, Inbred BALB C | 2 | 2019 | 296 | 0.060 |
Why?
| Drug Synergism | 2 | 2014 | 151 | 0.060 |
Why?
| Genetic Predisposition to Disease | 1 | 2007 | 511 | 0.060 |
Why?
| Jurkat Cells | 2 | 2014 | 27 | 0.060 |
Why?
| Zebrafish Proteins | 1 | 2003 | 21 | 0.060 |
Why?
| Extracellular Matrix Proteins | 1 | 2004 | 68 | 0.060 |
Why?
| Adipogenesis | 1 | 2024 | 49 | 0.060 |
Why?
| Steroids | 1 | 2024 | 57 | 0.050 |
Why?
| Ovariectomy | 1 | 2024 | 115 | 0.050 |
Why?
| PPAR gamma | 1 | 2024 | 65 | 0.050 |
Why?
| Sequence Analysis, RNA | 1 | 2024 | 88 | 0.050 |
Why?
| Integrin beta Chains | 1 | 2023 | 13 | 0.050 |
Why?
| Integrins | 1 | 2023 | 30 | 0.050 |
Why?
| Chromosomes, Human, Pair 13 | 1 | 2003 | 34 | 0.050 |
Why?
| Oxidative Phosphorylation | 1 | 2023 | 41 | 0.050 |
Why?
| Receptors, Fibroblast Growth Factor | 1 | 2002 | 8 | 0.050 |
Why?
| Cytogenetic Analysis | 1 | 2023 | 74 | 0.050 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2002 | 30 | 0.050 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2002 | 66 | 0.050 |
Why?
| Chromosome Deletion | 1 | 2023 | 134 | 0.050 |
Why?
| Macrophage Activation | 1 | 2022 | 25 | 0.050 |
Why?
| Oncogene Proteins, Fusion | 1 | 2002 | 57 | 0.050 |
Why?
| Porphyromonas gingivalis | 1 | 2022 | 14 | 0.050 |
Why?
| Geography | 1 | 2022 | 60 | 0.050 |
Why?
| Computational Biology | 2 | 2020 | 215 | 0.050 |
Why?
| Chromatin | 1 | 2023 | 137 | 0.050 |
Why?
| Uterine Cervical Neoplasms | 1 | 2005 | 276 | 0.050 |
Why?
| Diploidy | 3 | 2007 | 26 | 0.050 |
Why?
| Inflammasomes | 1 | 2022 | 62 | 0.050 |
Why?
| DNA, Neoplasm | 1 | 2002 | 143 | 0.050 |
Why?
| Models, Animal | 2 | 2015 | 227 | 0.050 |
Why?
| Mutation Rate | 1 | 2021 | 35 | 0.050 |
Why?
| DNA Primers | 2 | 2015 | 206 | 0.050 |
Why?
| Clone Cells | 1 | 2021 | 70 | 0.050 |
Why?
| Proteins | 1 | 2003 | 339 | 0.040 |
Why?
| Genes, Tumor Suppressor | 1 | 2021 | 73 | 0.040 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 67 | 0.040 |
Why?
| HCT116 Cells | 1 | 2020 | 21 | 0.040 |
Why?
| DNA Copy Number Variations | 1 | 2021 | 109 | 0.040 |
Why?
| Ovarian Neoplasms | 1 | 2004 | 450 | 0.040 |
Why?
| Cytokines | 3 | 2009 | 606 | 0.040 |
Why?
| Wnt Signaling Pathway | 1 | 2021 | 86 | 0.040 |
Why?
| Double-Blind Method | 2 | 2014 | 708 | 0.040 |
Why?
| 3' Untranslated Regions | 1 | 2020 | 52 | 0.040 |
Why?
| Immunohistochemistry | 3 | 2009 | 957 | 0.040 |
Why?
| Software | 1 | 2002 | 276 | 0.040 |
Why?
| DNA | 1 | 2023 | 535 | 0.040 |
Why?
| Gene Knockout Techniques | 1 | 2019 | 39 | 0.040 |
Why?
| Genetic Variation | 1 | 2020 | 207 | 0.040 |
Why?
| Drug Discovery | 1 | 2020 | 85 | 0.040 |
Why?
| Crystallography, X-Ray | 1 | 2019 | 147 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 169 | 0.040 |
Why?
| Protein Phosphatase 2 | 1 | 2019 | 4 | 0.040 |
Why?
| Protein Conformation | 1 | 2019 | 162 | 0.040 |
Why?
| G1 Phase | 1 | 2019 | 13 | 0.040 |
Why?
| Multivariate Analysis | 1 | 2021 | 583 | 0.040 |
Why?
| Enzyme Activators | 1 | 2019 | 8 | 0.040 |
Why?
| Immunotherapy | 1 | 2021 | 235 | 0.040 |
Why?
| Mice, Nude | 1 | 2019 | 248 | 0.040 |
Why?
| Antibody-Dependent Cell Cytotoxicity | 2 | 2009 | 12 | 0.040 |
Why?
| Structure-Activity Relationship | 1 | 2020 | 395 | 0.040 |
Why?
| Wnt Proteins | 2 | 2013 | 98 | 0.040 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2019 | 78 | 0.040 |
Why?
| DNA Methylation | 1 | 2023 | 550 | 0.040 |
Why?
| Phosphorylation | 1 | 2020 | 525 | 0.040 |
Why?
| Drug Resistance | 1 | 2018 | 65 | 0.040 |
Why?
| Autophagy | 1 | 2020 | 170 | 0.040 |
Why?
| Cell Cycle Checkpoints | 1 | 2017 | 29 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2022 | 1610 | 0.030 |
Why?
| Cell Hypoxia | 1 | 2016 | 82 | 0.030 |
Why?
| Chronic Disease | 1 | 2019 | 573 | 0.030 |
Why?
| Biological Transport | 1 | 2016 | 164 | 0.030 |
Why?
| Endoplasmic Reticulum Stress | 1 | 2016 | 40 | 0.030 |
Why?
| Models, Statistical | 2 | 2008 | 226 | 0.030 |
Why?
| Drug Interactions | 1 | 2016 | 206 | 0.030 |
Why?
| Cell Line | 2 | 2013 | 988 | 0.030 |
Why?
| Mice, Inbred ICR | 1 | 2016 | 23 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2016 | 119 | 0.030 |
Why?
| Microscopy, Electron, Transmission | 1 | 2015 | 75 | 0.030 |
Why?
| Pharmacogenetics | 2 | 2006 | 50 | 0.030 |
Why?
| Vidarabine | 1 | 2015 | 9 | 0.030 |
Why?
| Mitoxantrone | 1 | 2015 | 8 | 0.030 |
Why?
| Reoviridae | 1 | 2015 | 25 | 0.030 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2015 | 45 | 0.030 |
Why?
| Vincristine | 1 | 2015 | 82 | 0.030 |
Why?
| China | 1 | 2015 | 90 | 0.030 |
Why?
| Vaccination | 2 | 2007 | 280 | 0.030 |
Why?
| Prednisone | 1 | 2015 | 101 | 0.030 |
Why?
| Ligands | 1 | 2015 | 203 | 0.030 |
Why?
| Glutathione Peroxidase | 1 | 2014 | 23 | 0.030 |
Why?
| Molecular Targeted Therapy | 1 | 2016 | 123 | 0.030 |
Why?
| Cyclin B | 1 | 2014 | 4 | 0.030 |
Why?
| Microscopy, Fluorescence | 1 | 2015 | 158 | 0.030 |
Why?
| Risk Assessment | 2 | 2009 | 1270 | 0.030 |
Why?
| Cyclophosphamide | 1 | 2015 | 168 | 0.030 |
Why?
| Disulfiram | 1 | 2014 | 13 | 0.030 |
Why?
| CDC2 Protein Kinase | 1 | 2014 | 16 | 0.030 |
Why?
| Portraits as Topic | 1 | 2014 | 2 | 0.030 |
Why?
| Glucose | 1 | 2016 | 341 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2014 | 36 | 0.030 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2013 | 9 | 0.030 |
Why?
| Chemotherapy, Adjuvant | 1 | 2014 | 121 | 0.030 |
Why?
| Lectins, C-Type | 1 | 2013 | 30 | 0.030 |
Why?
| Veratrum Alkaloids | 1 | 2013 | 5 | 0.030 |
Why?
| Multidrug Resistance-Associated Proteins | 1 | 2013 | 16 | 0.030 |
Why?
| Isoxazoles | 1 | 2013 | 14 | 0.030 |
Why?
| G1 Phase Cell Cycle Checkpoints | 1 | 2013 | 16 | 0.030 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2013 | 29 | 0.030 |
Why?
| Glutathione | 1 | 2014 | 299 | 0.030 |
Why?
| Hedgehog Proteins | 1 | 2013 | 32 | 0.030 |
Why?
| Sulfones | 1 | 2013 | 24 | 0.030 |
Why?
| Itraconazole | 1 | 2013 | 35 | 0.030 |
Why?
| Peptide Library | 1 | 2013 | 16 | 0.030 |
Why?
| Receptors, Glucocorticoid | 1 | 2013 | 32 | 0.030 |
Why?
| Receptors, IgG | 1 | 2013 | 22 | 0.030 |
Why?
| Azacitidine | 1 | 2013 | 34 | 0.030 |
Why?
| Oxidants | 1 | 2013 | 54 | 0.030 |
Why?
| ADP-ribosyl Cyclase | 2 | 2003 | 5 | 0.030 |
Why?
| Epitopes | 1 | 2013 | 59 | 0.030 |
Why?
| Hydrocortisone | 1 | 2013 | 110 | 0.030 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 93 | 0.030 |
Why?
| MAP Kinase Signaling System | 1 | 2013 | 117 | 0.030 |
Why?
| Prospective Studies | 2 | 2010 | 2378 | 0.030 |
Why?
| Hydrogen Peroxide | 1 | 2013 | 113 | 0.030 |
Why?
| Histone Deacetylases | 1 | 2013 | 50 | 0.030 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 128 | 0.030 |
Why?
| Radiation, Ionizing | 1 | 2013 | 100 | 0.020 |
Why?
| Osteoblasts | 2 | 2006 | 462 | 0.020 |
Why?
| Transcriptome | 1 | 2014 | 313 | 0.020 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2012 | 45 | 0.020 |
Why?
| Viper Venoms | 1 | 2011 | 7 | 0.020 |
Why?
| Protein C | 1 | 2011 | 18 | 0.020 |
Why?
| Risk | 1 | 2011 | 324 | 0.020 |
Why?
| Bone Density Conservation Agents | 1 | 2010 | 74 | 0.020 |
Why?
| Diphosphonates | 1 | 2010 | 90 | 0.020 |
Why?
| Databases as Topic | 1 | 2009 | 37 | 0.020 |
Why?
| Parathyroid Hormone | 1 | 2010 | 149 | 0.020 |
Why?
| Lymphocytes | 1 | 2010 | 149 | 0.020 |
Why?
| Cytoskeleton | 1 | 2008 | 39 | 0.020 |
Why?
| Genotype | 1 | 2009 | 533 | 0.020 |
Why?
| Twins | 1 | 2007 | 20 | 0.020 |
Why?
| STAT Transcription Factors | 1 | 2007 | 8 | 0.020 |
Why?
| Cytological Techniques | 1 | 2007 | 14 | 0.020 |
Why?
| NF-kappa B p52 Subunit | 1 | 2007 | 6 | 0.020 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 226 | 0.020 |
Why?
| NF-kappa B p50 Subunit | 1 | 2007 | 16 | 0.020 |
Why?
| I-kappa B Kinase | 1 | 2007 | 20 | 0.020 |
Why?
| Karyotyping | 1 | 2007 | 65 | 0.020 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2007 | 63 | 0.020 |
Why?
| HLA-A2 Antigen | 1 | 2007 | 11 | 0.020 |
Why?
| Antigen Presentation | 1 | 2007 | 25 | 0.020 |
Why?
| Benzamides | 1 | 2007 | 50 | 0.020 |
Why?
| Remission Induction | 1 | 2007 | 208 | 0.020 |
Why?
| Polysaccharide-Lyases | 1 | 2007 | 6 | 0.020 |
Why?
| Leukocytes, Mononuclear | 1 | 2007 | 118 | 0.020 |
Why?
| Plasmids | 1 | 2007 | 164 | 0.020 |
Why?
| Tissue Culture Techniques | 1 | 2007 | 37 | 0.020 |
Why?
| Enzyme Activation | 1 | 2007 | 268 | 0.020 |
Why?
| Interferon-gamma | 1 | 2007 | 177 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 234 | 0.020 |
Why?
| Multigene Family | 1 | 2006 | 54 | 0.020 |
Why?
| Anticoagulants | 1 | 2009 | 256 | 0.020 |
Why?
| Piperazines | 1 | 2007 | 119 | 0.020 |
Why?
| Neoplasms, Experimental | 1 | 2007 | 110 | 0.020 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2006 | 49 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2010 | 1033 | 0.020 |
Why?
| Dendritic Cells | 1 | 2007 | 135 | 0.020 |
Why?
| Polymerase Chain Reaction | 1 | 2007 | 449 | 0.020 |
Why?
| Incidence | 1 | 2009 | 1032 | 0.020 |
Why?
| Receptors, Estrogen | 1 | 2007 | 132 | 0.020 |
Why?
| Chromosomes, Human | 1 | 2006 | 39 | 0.020 |
Why?
| Gelatinases | 1 | 2006 | 32 | 0.020 |
Why?
| Endopeptidases | 1 | 2006 | 65 | 0.020 |
Why?
| Rabbits | 1 | 2006 | 372 | 0.020 |
Why?
| Coculture Techniques | 1 | 2006 | 142 | 0.020 |
Why?
| Combined Modality Therapy | 1 | 2007 | 641 | 0.020 |
Why?
| Cyclin D3 | 1 | 2005 | 5 | 0.020 |
Why?
| Cyclin D2 | 1 | 2005 | 20 | 0.020 |
Why?
| Trisomy | 1 | 2005 | 27 | 0.020 |
Why?
| Adipocytes | 1 | 2006 | 126 | 0.020 |
Why?
| Oligonucleotide Probes | 1 | 2004 | 20 | 0.010 |
Why?
| Stem Cells | 1 | 2006 | 166 | 0.010 |
Why?
| Epithelium | 1 | 2004 | 66 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 2006 | 778 | 0.010 |
Why?
| Endothelium, Vascular | 1 | 2006 | 251 | 0.010 |
Why?
| Ovary | 1 | 2004 | 103 | 0.010 |
Why?
| Endothelial Cells | 1 | 2006 | 258 | 0.010 |
Why?
| Databases, Factual | 1 | 2007 | 673 | 0.010 |
Why?
| Bacterial Proteins | 1 | 2007 | 367 | 0.010 |
Why?
| RNA, Complementary | 1 | 2003 | 2 | 0.010 |
Why?
| Autocrine Communication | 1 | 2003 | 8 | 0.010 |
Why?
| Paracrine Communication | 1 | 2003 | 12 | 0.010 |
Why?
| Metaphase | 1 | 2003 | 45 | 0.010 |
Why?
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2002 | 18 | 0.010 |
Why?
| Cell Separation | 1 | 2003 | 92 | 0.010 |
Why?
| Biopsy | 1 | 2005 | 588 | 0.010 |
Why?
| Melanoma-Specific Antigens | 1 | 2002 | 3 | 0.010 |
Why?
| NAD+ Nucleosidase | 1 | 2002 | 3 | 0.010 |
Why?
| Cell Communication | 1 | 2003 | 68 | 0.010 |
Why?
| Antigens, Differentiation | 1 | 2002 | 17 | 0.010 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2003 | 134 | 0.010 |
Why?
| Cohort Studies | 1 | 2006 | 1452 | 0.010 |
Why?
| Immunoglobulins | 1 | 2002 | 81 | 0.010 |
Why?
| Database Management Systems | 1 | 2002 | 28 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2005 | 1197 | 0.010 |
Why?
| Logistic Models | 1 | 2003 | 900 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2003 | 1548 | 0.010 |
Why?
|
|
Zhan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|